Synthetic cannabinoids use in a sample of opioid-use disorder patients
Alías Ferri, María (Institut Hospital del Mar d'Investigacions Mèdiques)
Pellegrini, Manuela (National Centre on Istituto Superiore di Sanità (Itàlia))
Marchei, Emilia (Istituto Superiore di Sanità (Itàlia))
Pacifici, Roberta (Istituto Superiore di Sanità (Itàlia))
Rotolo, Maria Concetta (Istituto Superiore di Sanità (Itàlia))
Pichini, Simona (National Istituto Superiore di Sanità (Itàlia))
Pérez-Mañá, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Papaseit, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Muga, Roberto (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fonseca, Francina 1972- (Institut Hospital del Mar d'Investigacions Mèdiques)
Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Torrens, Marta (Institut Hospital del Mar d'Investigacions Mèdiques)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Cannabis is the most widely consumed illegal drug in the world and synthetic cannabinoids are increasingly gaining popularity and replacing traditional cannabis. These substances are a type of new psychoactive substance that mimics the cannabis effects but often are more severe. Since, people with opioids use disorder use widely cannabis, they are a population vulnerable to use synthetic cannabinoids. In addition, these substances are not detected by the standard test used in the clinical practice and drug-checking is more common in recreational settings. A cross-sectional study with samples of 301 opioid use disorder individuals was carried out at the addiction care services from Barcelona and Badalona. Urinalysis was performed by high-sensitivity gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-high -resolution mass spectrometry (UHPLC-HRMS). Any synthetic cannabinoid was detected in 4. 3% of the individuals and in 23% of these samples two or more synthetic cannabinoids were detected. Among the 8 different synthetic cannabinoids detected, most common were JWH-032 and JWH-122. Natural cannabis was detected in the 18. 6% of the samples and only in the 0. 7% of them THC was identified. Several different synthetic cannabinoids were detected and a non-negligible percentage of natural cannabis was detected among our sample. Our results suggest that the use of synthetic cannabinoids may be related to the avoidance of detection. In the absence of methods for the detection of these substances in clinical practice, there are insufficient data and knowledge making difficult to understand about this phenomenon among opioid use disorder population.
Grants:	Instituto de Salud Carlos III PI17/01962 Instituto de Salud Carlos III PI20/00804
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Cannabis ; New psychoactive substances ; Opioid use disorder ; Synthetic cannabinoid ; Urine sample analysis
Published in:	Frontiers in psychiatry, Vol. 13 (august 2022) , ISSN 1664-0640

DOI: 10.3389/fpsyt.2022.956120
PMID: 35990071

5 p, 154.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles